Long Noncoding RNA SNHG1 Promotes TERT Expression by Sponging miR-18b-5p in Breast Cancer

Yujuan Kang

Tumor Hospital of Harbin Medical University

Lin Wan

Tumor Hospital of Harbin Medical University

Qin Wang

Tumor Hospital of Harbin Medical University

Yanling Yin

Tumor Hospital of Harbin Medical University

Jiena Liu

Tumor Hospital of Harbin Medical University

Lei Liu

Tumor Hospital of Harbin Medical University

Hao Wu

Tumor Hospital of Harbin Medical University

Shouping Xu

Tumor Hospital of Harbin Medical University

Da Pang (✉ pangda@ems.hrbmu.edu.cn)

Tumor Hospital of Harbin Medical University

Research

Keywords: SNHG1, TERT, Breast cancer, Competing endogenous RNA, E2F1

Posted Date: February 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-218768/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Long noncoding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) plays a positive role in the progression of human malignant tumors. However, the molecular mechanism of SNHG1 remains elusive in breast cancer.

Methods: The Cancer Genome Atlas data were used to examine the differential expression of SNHG1 in tumor and normal tissues, as well as the relationship between SNHG1 expression and prognosis. Oncogenic role of SNHG1 in breast cancer was studied both *in vitro* and *in vivo*. Animal experiments along with colony counting kit-8, colony formation, wound healing, and Transwell invasion assays were used to verify that SNHG1 was an oncogene in breast cancer. Furthermore, reverse transcription-polymerase chain reaction, western blotting analysis, subcellular RNA fractionation, and dual-luciferase reporter assay were performed to prove the competing endogenous RNA (ceRNA) mechanism of SNHG1, miR-18b-5p, and telomerase reverse transcriptase (TERT). Finally, chromatin immunoprecipitation was performed to confirm that the transcription factor E2F1 could enhance SNHG1 transcription.

Results: LncRNA SNHG1 was upregulated and had a positive relationship with poor prognosis according to bioinformatics analysis. Silencing SNHG1 inhibited tumorigenesis in breast cancer both *in vitro* and *in vivo*. Mechanistically, SNHG1 functioned as a ceRNA to promote TERT expression by sponging miR-18b-5p. Moreover, miR-18b-5p acted as a tumor repressor in breast cancer. Finally, E2F1, a transcription factor, enhanced SNHG1 transcription.

Conclusions: Our results provide a comprehensive understanding of the oncogenic mechanism of lncRNA SNHG1 in breast cancer. Importantly, we identified a novel E2F1–SNHG1–miR-18b-5p–TERT axis, which may be a potential therapeutic target for breast cancer.

Background

Long noncoding RNAs (lncRNAs) are a large family of RNAs with limited protein-coding potential, length of over 200 nucleotides, and lack of a detectable open reading frame[1–5]. Importantly, lncRNA dysregulation has been observed in various cancers, and they reportedly participate in cancer cell growth, metastasis, and drug resistance[6, 7]. Moreover, lncRNAs are a novel class of potential biomarkers and therapeutic targets for cancer treatment[8]. In terms of regulatory mechanisms, when lncRNAs are located in the nucleus, they regulate gene expression by acting as epigenetic modulators[9, 10]; whereas, most lncRNAs in the cytoplasm harbor multiple binding sites for identical microRNAs (miRNAs), and are called competing endogenous RNAs (ceRNAs)[11]. miRNAs are a class of pervasive, conserved, small, noncoding RNAs that act as negative gene regulators to repress the expression of target genes[12]. ceRNAs can sequester miRNAs and protect the target mRNAs from being repressed[13, 14]. LncRNA small nucleolar RNA host gene 1 (SNHG1) is localized at 11q12.3 and shows upregulated expression in various cancers, including glioma and lung cancer[15–17]. In addition, SNHG1 reportedly serves as an oncogene

in human cancers[18]. For instance, Cui *et al.* have shown that SNHG1 promotes the progression of pancreatic cancer via the Notch-1 signaling pathway[19].

Telomeres are cellular nucleoprotein complexes that maintain chromosomal integrity and genome stability[20]. Telomeres are formed by hexameric repeats of a 5'-TTAGGG-3' sequence ending in a 3' single-stranded overhang, the G-strand overhang[21, 22] that protects the genomic DNA from the continued erosion of telomeres during cell division. Human telomerase is composed of two main core subunits: TERT, which constitutes the catalytic subunit and telomerase RNA component, which provides a template for telomerase elongation[23–25]. Human TERT protein levels are rate-limiting for telomerase activity and telomere length homeostasis[26]. A positive correlation between TERT mRNA expression and telomerase activity has been observed, thereby suggesting that telomerase is primarily regulated by TERT gene expression[24, 27, 28]. In approximately 90% of human tumors, telomerase is either upregulated or reactivated to maintain the telomeres during numerous rounds of cell divisions that are required for the emergence of malignant and metastatic diseases[29]. In cancer cells, TERT activity shows differential upregulation that is possibly due to several processes, such as transcriptional regulation, alternate RNA splicing, and post-translational modifications such as protein phosphorylation[26, 30]. Breast cancer is one of the leading mortal causes from cancer among women worldwide[31, 32]. Surgery, radiotherapy, chemotherapy and hormone therapy are still the main and common therapeutic approaches to treat breast cancer[33]. It was reported that the mRNA expression of TERT in breast cancer samples has a positive relationship with poor prognosis[34]. However, to date, no studies have determined the mechanism of the relationship between SNHG1 and TERT in breast cancer. Thus, in this study, we attempted to elucidate the oncogenic function of SNHG1 in breast cancer. To the best of our knowledge, this is the first study to report that a E2F1–SNHG1–miR-18b-5p–TERT axis is involved in breast cancer, and this axis may be a novel potential therapeutic target for the same.

Materials And Methods

Public data access and analysis

The genome-wide SNHG1 expression and prognosis data were downloaded from TCGA database (<https://tcga-data.nci.nih.gov/>). SNHG1 expression was dichotomized using median expression as the cutoff to define “high value” at or above the median versus “low value” below the median. GEPIA database (<http://gepia.cancer-pku.cn/>) and TCGA database were used to predict the relationship between SNHG1 and TERT. Prognoscan (<http://dna00.bio.kyutech.ac.jp/PrognoScan/index.html>)[35] and KM plotter (<http://kmplot.com/analysis/>) were used to examine the survival of breast cancer patients according to differential SNHG1 expression level.

Cell culture

MDA-MB-468, Hs578T, HEK293T, MDA-MB-231 and 4T1 cell lines were obtained from the Chinese Academy of Sciences Cell Bank. MDA-MB-468, Hs578T, HEK293T and 4T1 were cultured with DMEM medium (Gibco, Waltham, MA) and 10% fetal bovine serum (FBS; Gibco), 100 u/mL penicillin and grown at 37°C with 5% CO₂ (Thermo). MDA-MB-231 was cultured with L15 (Gibco, Waltham, MA) medium and 10% FBS, 100 u/mL penicillin and grown at 37°C with air incubator (Thermo).

Breast specimens

Breast cancer tissues and paired normal tissues were obtained from Harbin Medical University Cancer Center (HMUCC). For RNA extraction, fresh tissue from individuals with breast cancer and normal controls was collected and stored at -80°C immediately resection. The expression level of SNHG1 and TERT were measured by RT-qPCR.

RNA extraction and RT-PCR

Total RNA samples from cells samples were isolated using Trizol reagent (Invitrogen, USA) according to manufacturer's protocols. Total RNA (0.5µg) was then reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit (Roche, USA) to obtain cDNA. The SYBR Green PCR Master Mix Kit (Applied Biosystems, USA) was used to quantify the RNA levels using SYBR Green PCR Master Mix Kit, and the results were normalized against GAPDH and U6 expression levels using the $2^{-\Delta\Delta CT}$ method. The RT-qPCR was performed on ABI StepOne Real-time PCR System (Applied Biosystems, USA). The primer sequences are as follows: SNHG1-F: 5'-AACTTCCCATAACTCCACTTC-3'; SNHG1-R: 5'-ACAACCAACACAGCAACAC-3'; TERT-F: 5'-CTGTACTTTGTCAAGGTGGATGTGA-3'; TERT-R: 5'-ACGTGTTCTGGGGTTTGATGATG-3'; Hsa-miR-18b-5p-F: 5'-CGGGCTAAGGTGCATCTAGTGC-3'; Hsa-miR-18b-5p-R: 5'-ATCCAGTGCAGGGTCCGAGG-3'; Hsa-miR-18b-5p-RT: 5'-GTCGTATCCAGTGCAGGGTCCGAGGTCCGAGGTATTGCACTGGATACGACCTAACA-3'; hsa-U6-F: 5'-GCTTCGGCAGCACATATACTAAAAT-3'; hsa-U6-R: 5'-CGCTTCACGAATTTGCGTGTGCAT-3'; hsa-U6-RT: 5'-CGCTTCACGAATTTGCGTGTGCAT-3'; GAPDH-F: 5'-CATGTTTCGTGCATGGGTGTGAA-3'; GAPDH-R: 5'-GGCATGGACTGTGGTCATGAG-3'; E2F1-F: 5'-ACGTGACGTGTCAGGACCT-3'; E2F1-R: 5'-GATCGGGCCTTGTCTTCTCTT-3'; Mus-TERT-F: 5'-TCTACCGCACTTTGGTTGCC-3'; Mus-TERT-R: 5'-CAGCACGTTTCTCTCGTTGC-3'.

Transfection of small interfering RNAs and miRNA mimics/inhibitors

LncRNA SNHG1 short interfering RNA (siRNAs), hsa-miR-18b-5p mimics and hsa-miR-18b-5p inhibitor were synthesized by Ribo Co., Ltd. (Guangdong, China). Cells were seeded in 6-well plate, when the cells grow 70-80 % confluence for miRNA or siRNA transfection. Cells were transfected using jetPRIME (Polyplus transfection). The sequences are as follows: si-SNHG1 #1 sense: GGUUUGCUGUGUAUCAUTT

antisense: AUGUGAUACACAGCAAACCTT; si-SNHG1#2 sense: GACCUAGCUUGUUGCCAAUTT antisense: AUUGGCAACAAGCUAGGUCTT; si-Control sense :UUCUCCGAACGUGUCACGUTT antisense: ACGUGACACGUUCGGAGAATT; si-E2F1#1 sense: GAGACCTCTTCGACTGTGA; si-E2F1#2 sense: CTATGAGACCTCACTGAAT; si-E2F1#3: GGGAGAAGTCACGCTATGA; hsa-miR-18b-5p mimics sense :UAAGGUGCAUCUAGUGCAGUUAG antisense: AACUGCACUAGAUGCACCUUAUU; hsa-miR-18b-5p inhibitor sense: CUAACUGCACUAGAUGCACCUUA.

Lentiviral transfection

For lentiviral transfection, moderate lentiviruses were used to infect 4T1 cells in a 6-well plate with 4-6 µg/ml polybrene (#107689, Sigma). The infected cells were then subjected to selection with 1 µg/ml puromycin (#540411, Calbiochem, USA) cultured for several days. The stable knockdown of snhg1 was examined by RT-qPCR. The sequence of lentivirus: sh-snhg1#1: CTGGTGACAAATCTCAGGCAT; sh-snhg1#2: GTGGTTCATCTCAAAGCCCTT; sh-snhg1#3: AAGGATAGGAACAGAAATCAT.

Cell viability assay

The viability of treated cells was estimated by a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) assay according to the manufacturer' instructions and as previous described [36]. Briefly, cells were plated at a density of 5×10^3 cells/well with 100µL of DMEM+10% FBS in 96-well microtiter plates. 10µL CCK-8 solution was added to each well which including 100µL DMEM medium, and then the plate was incubated at 37°C for 60 minutes. Next, the absorbance of each well was measured by a microplate reader at a wavelength of 450 nm. Medium containing 10% CCK-8 served as a control.

Colony formation assay

1×10^3 cells were seeded in 6-well plate and cultured in medium containing 10% FBS for 14 days.

Discard the culture medium, PBS wash the 6-well plate three times. Colonies were fixed with methanol for 40 minutes, then 500µL of 5% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) were added to each well for 30 minutes. After staining, colonies were gently washed and counted.

Wound healing assay

Cells were seeded in 6-well plate, transfected with siRNAs or miRNA mimics according to previous method. When cell confluence reached 100%, 10µL pipette was used to scratch on the bottom of the 6-well plate. The scratched cells were washed away. Then taking photos in 0 h, 24 h, 48 h.

Transwell invasion assay

Transwell invasion assay was performed using a Transwell plate (Corning, New York, USA) was coated with Matrigel (Sigma-Aldrich, USA). 5×10^4 cells in serum-free medium were suspended in upper chamber with Matrigel. Medium containing 20% FBS (Seratech, PAN) was added to the bottom chamber. After incubating at 37°C for 48 h. Then discard the culture medium, cells that invaded to the lower side of the Transwell were fixed with methanol, stained with 0.5% crystal violet and imaged under a microscope. Image J was used to count the number of cells.

Animal experiment

4-5 weeks old female Balb/C mice were purchased from Animal Center of the Second Affiliated Harbin Medical University. 4T1 cells stably expressing sh-scramble and sh-snhg1 were resuspended with DMEM medium. Then 100 μ l of serum-free medium containing 5×10^4 cells were injected into the right mammary fat pad. The tumor volume was measured with a caliper every 2 days beginning on day 6 days after cell implantation. The tumor volume was calculated using the formula tumor volume = $1/2 (\text{length} \times \text{width}^2)$. Then the mice were euthanized, the weight of tumors in mouse were measured. Then, half of the tumors was extracted protein and the other half was extracted RNA.

Western blot assay

Cells were lysed with lysis buffer which containing 150 mmol/L NaCl, 1% Triton X-100, 5 mmol/L EDTA, 5000 U/mL aprotinin, 20 mg/mL leupeptin, 1 mmol/L phenyl-methylsulfonyl fluoride, 2 mmol/L sodium orthovanadate, 50 mmol/L NaF, 5% glycerol, 10 mmol/L Tris-HCl (pH 7.4), and 2% SDS. Then ultrasonic crusher was used to broken cell nucleus. After centrifugation at 13500g for 30 minutes, supernatant was collected. Next, protein concentrations were tested by BCA protein assay kit (#p0010; Beyotime, Shanghai, China). Then these proteins were separated by SDS-PAGE, followed by electroblotting onto a nitrocellulose membrane, which was blocked with 5% nonfat milk in 0.1% Tween 20-TBS overnight at 4°C. The membrane was incubated with primary antibody against TERT (#sc-377511; Santa cruz biotechnology), E2F1 antibody (#3742; Cell Signaling Technology) and β -actin (#sc-377511; Santa cruz biotechnology). After washing with Tween 20/TBS (TBST), the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies for 1h in room temperature. After washing with Tween 20/PBS (PBST), protein bands on the membrane were visualized by an enhanced chemiluminescence Western blotting detection system (Western Lightning; Perkin-Elmer, Norwalk, CT).

Dual-luciferase reporter gene assay

We cloned the full length of the 3' untranslated regions (UTRs) of human SNHG1 and TERT to generate reporter vectors with miRNA binding sites. The full length of 3' UTRs of human SNHG1 and TERT were

amplified by PCR and cloned into psi-CHECK-2 luciferase expression vector that contained Not1-XhoI sites. HEK293T cells were chosen to perform this assay. JetPRIME was used to transfect HEK293T with 20µmol/L hsa-miR-18b-5p mimic or negative control mimic and 0.5 mg of plasmid. The luciferase activities were measured 48 h after transfection using a dual-luciferase reporter assay kit (#E1910, Promega, USA) and a luminometer (GloMax 20/20, Promega, USA).

Cytoplasmic-nuclear RNA fractionation

Cytoplasmic and nuclear RNA extraction were separated using the cytoplasmic and nuclear RNA purification kit (#21000, NORGEN) as directed by the manufacturer. We harvested 3×10^6 cells (HEK293T, MDA-MB-468, and Hs578T), washed them with ice-cold PBS, and then resuspended these cells in the ice-cold cytoplasmic Lysis Buffer J for 5 minutes on ice. Then lysates were centrifuged at 13500g for 10 minutes at 4°C. The supernatant was collected as the cytoplasmic fraction, the remaining lysates was collected as the nuclear fraction. Finally, cytoplasm RNA and nucleus RNA were successfully separated. Then, the expression levels of GAPDH, U1 and SNHG1 in cytoplasm or nucleus were detected by RT-PCR.

Chromatin immunoprecipitation (ChIP)

Chromatin immunoprecipitation (ChIP) assays were performed using the ChIP Assay Kit (#p2078; Beyotime, Shanghai, China) according to the manufacturer's protocol. 2×10^7 cells were crosslinked with 1% formaldehyde, and this reaction was terminated after 20 min by the addition of glycine at a final concentration of 0.125 M. DNA was immunoprecipitated from sonicated cell lysates using an E2F1 antibody; IgG (BD Biosciences, San Diego, CA, USA) served as the negative control. Protein A/G Plus-agarose was purchased from Santa Cruz Biotechnology (#sc-2003). After RNase A and Proteinase K treatment, immunoprecipitated DNA was extracted by DNA purification kit (Beyotime, Shanghai, China). The immunoprecipitated DNA was subjected to PCR to amplify the E2F1 promoter binding sites. The amplified fragments were then analyzed on an agarose gel. Chromatin (1%) prior to immunoprecipitation was used as the input control. The primer sequences of binding site between E2F1 and SNHG1 were as follows: SNHG1-F: 5'-CAGGAGAATTGCTTGAACCCG-3'; SNHG1-R: 5'-TGGCCCGATCTCAGCTCACT-3'.

Nucleic acid electrophoresis

The DNA PCR products were investigated using 1% agarose gel electrophoresis with TAE running buffer. DNA was separated by electrophoresis at 100 V for 30 min. The DNA marker was Marker L (50-500 bp) (Sango Biotech, China). The bands were examined by UV irradiation (Biorad).

Statistical analyses

The expression of SNHG1 in cancer tissues compared with normal tissues were tested by a paired t-test. Kaplan–Meier method and log-rank test were used to evaluate the survival difference between patients with high SNHG1 expression and low SNHG1 expression. The differences in the results of the *in vitro* and *in vivo* experiments between groups were analyzed using Student's t-test. All the experiments were performed independently in triplicate. All statistical tests were two-sided, and $P < 0.05$ indicated statistical significance. Statistical analysis was performed using 332R.3.4 graphics software and GraphPad Prism software (GraphPad Software, USA).

Results

Expression of SNHG1 was upregulated in cancerous tissues and positively related to poor prognosis

To determine the expression level of SNHG1 in human pan-cancer tissues, TCGA data was downloaded and analyzed. SNHG1 expression level was higher in thyroid carcinoma (THCA), stomach adenocarcinoma (STAD), sarcoma (SARC), rectum adenocarcinoma (READ), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), liver hepatocellular carcinoma (LIHC), kidney renal papillary cell carcinoma (KIRP), kidney renal clear cell carcinoma (KIRC), kidney chromophobe (KICH), head and neck squamous cell carcinoma (HNSC), esophageal carcinoma (ESCA), colon adenocarcinoma (COAD), cholangiocarcinoma (CHOL), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA) than in normal tissues (Fig. 1a and supplementary Table 1). Furthermore, the expression of SNHG1 was also more upregulated in pan-cancer tissues than in normal tissues (Fig. 1b). We also examined five pairs of breast cancer tissues and normal breast tissues to determine SNHG1 expression and observed that SNHG1 showed higher expression level in breast cancer tissues than in paired normal tissues (Fig. 1c). The PrognScan database demonstrated that higher expression level of SNHG1 was associated with poor relapse-free survival (RFS) (Fig. 1d), and disease-specific survival (DSS) (Fig. 1e) in patients with breast cancer. In pan-cancer analysis, upregulated SNHG1 expression was also related to poor overall survival (OS) and DSS (Fig. 1f and g, supplementary Table 1). Moreover, higher expression of SNHG1 also correlated with poor prognosis in UCEC, LIHC, PRAD, and adrenocortical carcinoma (ACC) (Appendix Fig. 1a-k). We also use the KM plotter (<http://kmplot.com/analysis/>) to evaluate the prognostic value of SNHG1 in different cancers[37]. Higher expression of SNHG1 was correlated with poor OS in LIHC, KIRC, SARC and UCEC (supplementary Fig. 1l-o).

SNHG1 as an oncogene promoted tumorigenesis both *in vitro* and *in vivo*

Hs578T, MDA-MB-468, and MDA-MB-231 are breast cancer cell lines that have higher SNHG1 expression level than MCF10A cells (Fig. 2a); consequently, they were chosen for subsequent experiments. SNHG1 was knocked down by transfection with siSNHG1, and the transcription efficiency of siSNHG1 was evaluated using reverse transcription-polymerase chain reaction (RT-PCR) (Fig. 2b). Further, cell counting kit-8 (CCK-8), colony formation, wound healing, and Transwell invasion assays were performed to identify the function of SNHG1 in breast cancer. We observed that silencing of SNHG1 inhibited tumor cell proliferation and colony formation and suppressed tumor cell migration and invasion (Fig. 2c-f).

Subsequently, we evaluated the functions of SNHG1 *in vivo*. Specific mouse source virus was synthesized to construct a 4T1 stable knockdown of snhg1 (sh-snhg1). Knockdown efficiency was determined using RT-PCR, and we observed that the virus could knockdown snhg1 in 4T1, as expected (Fig. 2g). The CCK-8 assay showed that the sh-snhg1 group had poorer proliferation ability than the scramble group (Fig. 2h). Further, 4T1 scramble and 4T1 sh-snhg1 cells were subcutaneously injected into Balb/C female mice. As expected, the mice from the sh-snhg1 group had smaller tumors than those from the scramble group (Fig. 2i), thereby suggesting that SNHG1 acted as an oncogene *in vivo* as well. Moreover, the median tumor weight in the sh-snhg1 group was lower than that in the control group (Fig. 2j). The tumorigenesis and tumor tissue of each group of Balb/C mice are shown as Fig. 2k. Thus, the abovementioned results showed that SNHG1 acted as an oncogene in breast cancer both *in vitro* and *in vivo*.

SNHG1 boosted TERT expression

Then, TCGA data was downloaded to evaluate the correlation between SNHG1 and TERT in pan-cancer and breast cancer. The results showed that TERT is positively correlated with SNHG1 in pan-cancer scope (Fig. 3a and supplementary Table 2) and breast cancer scope (Fig. 3b). In addition, the Gene Expression Profiling Interactive Analysis (GEPIA) was used to verify this relationship, and the results showed that TERT was positively correlated with SNHG1 (Fig. 3c). The GEPIA database showed that TERT expression level was considerably higher in breast cancer tissues than in normal tissues (Fig. 3d). Just as Fig. 3e showed, TERT presents a higher expression level in breast cancer cell lines than in MCF10A cell. We also examined four pairs of breast cancer tissues and normal breast tissues to determine TERT expression and observed that TERT showed higher expression level in breast cancer tissues than in paired normal tissues (Fig. 3f).

SiSNHG1 was transfected into MDA-MB-468 and Hs578T cells, and RT-PCR was used to examine the transcription efficiency of siSNHG1 (Fig. 3g). Consequently, we observed that knockdown of SNHG1 downregulated the expression of TERT at both RNA (Fig. 3h) and protein levels in MDA-MB-468 (Fig. 3i) and Hs578T cells (Fig. 3j) in comparison to their levels in corresponding control groups. Furthermore, for the *in vivo* experiment, we extracted protein and RNA from mouse tumors and observed that the expression level of TERT in mouse tumors was lower in the sh-snhg1 group than in the control group (Fig. 3k).

miR-18b-5p acted as a tumor suppressor in breast cancer

We further explored the mechanism by which SNHG1 promoted the expression of TERT in breast cancer. First, LncLocator was used to predict the subcellular localization of SNHG1, and the results showed that SNHG1 was mainly localized in the cytoplasm (Fig. 4a). Consequently, a cytoplasmic-nuclear RNA fractionation kit was used to confirm the forward prediction results in HEK293T, MDA-MB-468, and Hs578T cells (Fig. 4b). Both methods implied that SNHG1 was mainly localized in the cytoplasm. Therefore, we hypothesized that cytoplasmic SNHG1 might regulate TERT mRNA by acting as a ceRNA of miRNAs. To confirm this hypothesis, we used miRbase, TargetScan, and starBase databases to predict the possible miRNAs that could interact with both SNHG1 and TERT, simultaneously (supplementary Table 3). The intersection of miRNAs acquired from these databases revealed 15 overlapping miRNAs (Fig. 4c). RT-PCR was used to determine the upregulated miRNAs after silencing SNHG1 in MDA-MB-468 (Fig. 4d) and Hs578T cells (Fig. 4e). Finally, miR-18b-5p and miR-383-5p were chosen for subsequent experiments. However, when miR-383-5p mimics were transfected into Hs578T cells, the expression of TERT was upregulated (Fig. 4f). Thus, miR-18b-5p was the only candidate for subsequent experiments. To explore the functions of miR-18b-5p in breast cancer, we performed CCK-8, colony formation, wound healing, and Transwell invasion assays by transfecting Hs578T, MDA-MB-468, and MDA-MB-231 cells with miR-18b-5p mimics. The transcription efficiency of miR-18b-5p mimics was verified by RT-PCR (Fig. 4g), and cell proliferation and colony formation were attenuated on transfecting miR-18b-5p mimics (Fig. 4h and i). Further, wound healing and Transwell invasion assays showed that overexpression of miR-18b-5p could inhibit tumor cell migration and invasion (Fig. 4j and k). Thus, the abovementioned experiments indicated that miR-18b-5p may act as a tumor suppressor in breast cancer.

SNHG1 acted as a ceRNA to enhance TERT expression by sponging miR-18b-5p

We further explored the regulatory mechanism of SNHG1, miR-18b-5p, and TERT in breast cancer. RT-PCR was used to evaluate the transfection efficiency of miR-18b-5p mimics (Fig. 5a). TERT RNA level was downregulated after transfecting miR-18b-5p mimics (Fig. 5b); whereas, the level was upregulated after transfecting an miR-18b-5p inhibitor (Fig. 5d). Accordingly, TERT protein level was downregulated after transfecting miR-18b-5p mimics (Fig. 5c), and upregulated after transfecting miR-18b-5p inhibitor (Fig. 5e). Further, overexpression of miR-18b-5p inhibited SNHG1 expression; however, downregulation of miR-18b-5p promoted SNHG1 expression in MDA-MB-468 and Hs578T cells (Fig. 5f and g). Furthermore, silencing SNHG1 and inhibiting miR-18b-5p weakened the downregulation of TERT protein level in MDA-MB-468 and Hs578T cells (Fig. 5h). Finally, the dual-luciferase reporter assay was used to demonstrate the binding relationship between SNHG1, miR-18b-5p, and TERT. As expected, wild-type 3'-untranslated region of TERT was regulated by miR-18b-5p, and this effect could be neutralized by mutating the binding sites in the luciferase reporter (Fig. 5i). Additionally, we obtained similar results for the regulation of SNHG1 (Fig. 5j). SNHG1 function was partially mediated by inhibiting miR-18b-5p in breast cancer cells.

We transfected siSNHG1 and miR-18b-5p inhibitor into breast cancer cells and observed that siSNHG1-mediated restraint in cell proliferation and invasion abilities could be partially rescued by co-transfection of miR-18b-5p inhibitor in Hs578T and MDA-MB-468 cells (Fig. 5k and l). In addition, the expression of miR-18b-5p was more upregulated in Balb/C mice with snhg1 knockdown than in the scramble group (N=5) (Fig. 5m), which was consistent with our previous conclusion.

E2F1 promoted SNHG1 transcription

We further focused on elucidating the upstream transcription regulation mechanism of SNHG1. First, PROMO database was used to predict potential transcription factors (TFs) that could bind to the SNHG1 promoter (supplementary Table 4). We focused on E2F1, a prominent TF that mediates transcriptional activation in a variety of tumors.

To verify this prediction, we transfected MDA-MB-468, Hs578T, and HEK293T cells with an siRNA to silence E2F1. Knockdown efficiency was examined by RT-PCR (Fig. 6a) and western blotting analysis (Fig. 6b). RT-PCR showed that the expression level of SNHG1 (Fig. 6c) and TERT (Fig. 6d) in the siE2F1 group was lower than that in the control group. Further, the JASPAR database was used to predict the potential binding site between E2F1 and SNHG1 promoter (Fig. 6e and f, supplementary Table 5). Finally, chromatin immunoprecipitation-PCR assay indicated that in comparison with the Mock group, E2F1 was enriched at the SNHG1 promoter in Hs578T and HEK293T cells (Fig. 6g-h). A schematic illustration of this study is shown in Fig. 6i.

Discussion

Numerous studies have highlighted the functions of these regulatory lncRNAs in many biological processes, such as cancer development, stem cell differentiation, and chemotherapy resistance[38]. For instance, lncHOST2 act as a sponge of let-7b, thus increasing STAT3 expression and leading to breast cancer tumorigenesis[39]. SNHG1 promotes tumor growth by regulating the transcription of both local and distal genes[40]. TERT boosts epithelial-mesenchymal transformation and stemness, thereby indicating an important role in cancer progression[41]. This study revealed that SNHG1 was an oncogene that promoted the expression of TERT in breast cancer.

When lncRNAs are in the cytoplasm, they participate in modulating mRNA stability, regulating mRNA translation, serving as ceRNAs, and functioning as precursors of miRNAs[42]. Here, subcellular fractionation confirmed that SNHG1 was mainly located in the cytoplasm in breast cancer cell lines implying that SNHG1 acted as a ceRNA to enhance TERT expression by sponging miR-18b-5p in breast cancer.

To further explore the tumorigenesis mechanism of SNHG1 in breast cancer, we explored the upstream regulation of SNHG1. Notably, we observed that E2F1 could bind to the SNHG1 promoter and enhance its transcription in breast cancer. To summarize, this study uncovered a novel mechanistic axis, E2F1–

SNHG1–miR-18b-5p–TERT, in breast cancer tumorigenesis, and this axis may be a potential therapeutic target for breast cancer. However, we haven't studied the regulatory mechanism of SNHG1 which located in nucleus, and we will continue this study in near future.

Abbreviations

ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast carcinoma; CCK-8: cell counting Kit-8; ceRNA: competing endogenous RNA; CESC: Cervical and endocervical cancers; ChIP: Chromatin immunoprecipitation; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; DSS: disease specific survival; EMT: epithelial mesenchymal transformation; ESCA: esophageal carcinoma; HNSC: head and neck squamous cell carcinoma; GEPIA: Gene Expression Profiling Interactive Analysis; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LncRNA: Long noncoding RNAs; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; miRNA: microRNA; ORF: open reading frame; OS: overall survival; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; RFS: relapse free survival; SARC: sarcoma; siRNA: short interfering RNA; SNHG1: small nucleolar RNA host gene1; STAD: stomach adenocarcinoma; TCGA: The Cancer Genome Atlas; TERC: telomerase RNA component; TERT: telomerase reverse transcriptase; TF: transcription factor; THCA: thyroid carcinoma; TNBC: triple negative breast cancer; UCEC: uterine corpus endometrial carcinoma; UTRs: untranslated regions.

Declarations

Acknowledgments

None.

Funding

This work was supported by funding from the Project Nn10 of Harbin Medical University Cancer Hospital (Grant Number Nn102017- 02), the National Natural Science Foundation of China (Grant Number 82072904, 81872149, 81972706), Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation (Grant Number YQ2019H027), Distinguished Young Scholars of Harbin Medical University Cancer Hospital (Grant Number JCQN2018-03), Yong Elite Training Foundation Grant of Harbin Medical University Cancer Hospital (Grant Number JY2016-02) and Haiyan Fund Project of Harbin Medical University Cancer Hospital (Grant number JJQN 2018-10).

Availability of data and materials

All remaining data are availability within the article and supplementary files, or available from the authors upon request.

Ethics approval and consent to participate

All animal experiments were performed in accordance with the National Institutes of Health guide for the care and use of Laboratory animals and protocols approved by the Animal Ethics Committee of Harbin Medical University of Medicine and Health Sciences.

Consent for publication

All author shave agreed to publish this manuscript.

Competing interests

The authors declare no conflict of interest

Author details

1 Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150040, China

2 Heilongjiang Academy of Medical Sciences, Harbin, China

References

1. Lee S,F Kopp,T C Chang,A Sataluri,B Chen,S Sivakumar,H Yu,Y Xie,J T Mendell. Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins. *Cell*. 2016;164(1-2):69-80.
2. Niazi F,S Valadkhan. Computational analysis of functional long noncoding RNAs reveals lack of peptide-coding capacity and parallels with 3' UTRs. *RNA*. 2012;18(4):825-43.
3. Zhao J,X Song,K Wang. IncScore: alignment-free identification of long noncoding RNA from assembled novel transcripts. *Sci Rep*. 2016;634838.
4. Jia H,M Osak,G K Bogu,L W Stanton,R Johnson,L Lipovich. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. *RNA*. 2010;16(8):1478-87.
5. Saha A,S Bhattacharya,A Bhattacharya. Serum stress responsive gene EhsIncRNA of *Entamoeba histolytica* is a novel long noncoding RNA. *Sci Rep*. 2016;627476.
6. Gibb E A,C J Brown,W L Lam. The functional role of long non-coding RNA in human carcinomas. *Mol Cancer*. 2011;1038.

7. Spizzo R, M I Almeida, A Colombatti, G A Calin. Long non-coding RNAs and cancer: a new frontier of translational research? *Oncogene*. 2012;31(43):4577-87.
8. Bhan A, M Soleimani, S S Mandal. Long Noncoding RNA and Cancer: A New Paradigm. *Cancer Res*. 2017;77(15):3965-3981.
9. Verhoeven R J A, S Tong, B W Mok, J Liu, S He, J Zong, Y Chen, S W Tsao, M L Lung, H Chen. Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma. *Front Oncol*. 2019;9:1120.
10. Zhang J, S Sui, H Wu, J Zhang, X Zhang, S Xu, D Pang. The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer. *Cell Death Dis*. 2019;10(8):599.
11. Salmena L, L Poliseno, Y Tay, L Kats, P P Pandolfi. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell*. 2011;146(3):353-8.
12. Achkar N P, D A Cambiagno, P A Manavella. miRNA Biogenesis: A Dynamic Pathway. *Trends Plant Sci*. 2016;21(12):1034-1044.
13. Karreth F A, Y Tay, D Perna, U Ala, S M Tan, A G Rust, G Denicola, K A Webster, D Weiss, P A Perez-Mancera, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. *Cell*. 2011;147(2):382-95.
14. Tay Y, L Kats, L Salmena, D Weiss, S M Tan, U Ala, F Karreth, L Poliseno, P Provero, F Di Cunto, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. *Cell*. 2011;147(2):344-57.
15. Yan Y, Q Fan, L Wang, Y Zhou, J Li, K Zhou. LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cells. *Oncotarget*. 2017;8(22):35750-35760.
16. Li J, Z Zhang, L Xiong, C Guo, T Jiang, L Zeng, G Li, J Wang. SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. *Biochem Biophys Res Commun*. 2017;487(1):146-152.
17. Wang Q, Q Li, P Zhou, D Deng, L Xue, N Shao, Y Peng, F Zhi. Upregulation of the long non-coding RNA SNHG1 predicts poor prognosis, promotes cell proliferation and invasion, and reduces apoptosis in glioma. *Biomed Pharmacother*. 2017;91:906-911.
18. Liu L, Y Shi, J Shi, H Wang, Y Sheng, Q Jiang, H Chen, X Li, J Dong. The long non-coding RNA SNHG1 promotes glioma progression by competitively binding to miR-194 to regulate PHLDA1 expression. *Cell Death Dis*. 2019;10(6):463.
19. Cui L, Y Dong, X Wang, X Zhao, C Kong, Y Liu, X Jiang, X Zhang. Downregulation of long noncoding RNA SNHG1 inhibits cell proliferation, metastasis, and invasion by suppressing the Notch-1 signaling pathway in pancreatic cancer. *J Cell Biochem*. 2019;120(4):6106-6112.
20. Blackburn E H. Switching and signaling at the telomere. *Cell*. 2001;106(6):661-73.
21. Moyzis R K, J M Buckingham, L S Cram, M Dani, L L Deaven, M D Jones, J Meyne, R L Ratliff, J R Wu. A highly conserved repetitive DNA sequence, (TTAGGG)_n, present at the telomeres of human

- chromosomes. *Proc Natl Acad Sci U S A*. 1988;85(18):6622-6.
22. Makarov V L,Y Hirose,J P Langmore. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. *Cell*. 1997;88(5):657-66.
 23. Greider C W,E H Blackburn. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. *Nature*. 1989;337(6205):331-7.
 24. Lendvay T S,D K Morris,J Sah,B Balasubramanian,V Lundblad. Senescence mutants of *Saccharomyces cerevisiae* with a defect in telomere replication identify three additional EST genes. *Genetics*. 1996;144(4):1399-412.
 25. Lingner J,T R Cech. Purification of telomerase from *Euplotes aediculatus*: requirement of a primer 3' overhang. *Proc Natl Acad Sci U S A*. 1996;93(20):10712-7.
 26. Cong Y S,W E Wright,J W Shay. Human telomerase and its regulation. *Microbiol Mol Biol Rev*. 2002;66(3):407-25, table of contents.
 27. Li C,M Y Wu,Y R Liang,X Y Wu. Correlation between expression of human telomerase subunits and telomerase activity in esophageal squamous cell carcinoma. *World J Gastroenterol*. 2003;9(11):2395-9.
 28. Yi X,V M Tesmer,I Savre-Train,J W Shay,W E Wright. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. *Mol Cell Biol*. 1999;19(6):3989-97.
 29. Kim N W,M A Piatyszek,K R Prowse,C B Harley,M D West,P L Ho,G M Coviello,W E Wright,S L Weinrich,J W Shay. Specific association of human telomerase activity with immortal cells and cancer. *Science*. 1994;266(5193):2011-5.
 30. Cukusic A,N Skrobot Vidacek,M Sopta,I Rubelj. Telomerase regulation at the crossroads of cell fate. *Cytogenet Genome Res*. 2008;122(3-4):263-72.
 31. Siegel R L,K D Miller,A Jemal. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7-30.
 32. Chen W. Cancer statistics: updated cancer burden in China. *Chin J Cancer Res*. 2015;27(1):1.
 33. *Breast Cancer Treatment (Adult) (PDQ(R)): Patient Version*, in *PDQ Cancer Information Summaries*. 2002: Bethesda (MD).
 34. Elkak A,R Mokbel,C Wilson,W G Jiang,R F Newbold,K Mokbel. hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. *Anticancer Res*. 2006;26(6C):4901-4.
 35. Mizuno H,K Kitada,K Nakai,A Sarai. PrognoScan: a new database for meta-analysis of the prognostic value of genes. *BMC Med Genomics*. 2009;218.
 36. Kholodenko B N,O V Demin,G Moehren,J B Hoek. Quantification of short term signaling by the epidermal growth factor receptor. *J Biol Chem*. 1999;274(42):30169-81.
 37. Nagy A,A Lanczky,O Menyhart,B Gyorffy. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Sci Rep*. 2018;8(1):9227.
 38. Adams B D,C Parsons,L Walker,W C Zhang,F J Slack. Targeting noncoding RNAs in disease. *J Clin Invest*. 2017;127(3):761-771.

39. Hua K,X Deng,J Hu,C Ji,Y Yu,J Li,X Wang,L Fang. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer. *J Exp Clin Cancer Res.* 2020;39(1):58.
40. Sun Y,G Wei,H Luo,W Wu,G Skogerbo,J Luo,R Chen. The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes. *Oncogene.* 2017;36(49):6774-6783.
41. Yuan X,C Larsson,D Xu. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. *Oncogene.* 2019;38(34):6172-6183.
42. Rashid F,A Shah,G Shan. Long Non-coding RNAs in the Cytoplasm. *Genomics Proteomics Bioinformatics.* 2016;14(2):73-80.

Figures

Figure 1

Expression of SNHG1 was upregulated in cancerous tissues and positively related to poor prognosis. a: The Cancer Genome Atlas results showed that the expression level of SNHG1 was higher in THCA, STAD, SARC, READ, PRAD, PCPG, LUSC, LUAD, LIHC, KIRP, KIRC, KICH, HNSC, ESCA, COAD, CHOL, CESC, BRCA, BLCA than in normal tissues. b: Expression level of SNHG1 was also higher in pan-cancer tissues than in normal tissues. c: Expression level of SNHG1 was higher in breast cancer tissues than in normal tissue

((N=5 per group)). d and e: PrognoScan results showed that higher SNHG1 expression level had a positive association with poor overall survival (OS), relapse-free survival (RFS), and disease-specific survival (DSS) in breast cancer. f and g: Higher expression level of SNHG1 was related to poorer OS and DSS according to pan-cancer analysis. * P<.05; ** P<.01; *** P<0.001; **** P<.0001; NS, no significance.

Figure 2

SNHG1 acts as an oncogene promoted tumorigenesis both in vitro and in vivo. a: Expression of SNHG1 in MDA-MB-10A, Hs578T, MDA-MB-231, and MDA-MB-468 cell lines. b: Transfection efficacy of siSNHG1 in MDA-MB-468, Hs578T, and MDA-MB-231 cells. c: Colony counting kit-8 (CCK-8) showed that silencing SNHG1 inhibited tumor cell proliferation. d: Colony formation assay showed that silencing SNHG1 inhibited tumor cell clone formation. e: Wound healing assay proved that silencing SNHG1 suppressed tumor cell migration. f: Transwell invasion assay showed that knockdown of SNHG1 inhibited the invasion ability of tumor cells. g: Knockdown efficacy of lentiviral targeting of snhg1. h: CCK-8 showed that silencing of snhg1 suppressed 4T1 proliferation. i: Tumor growth curve of mice shows that sh-snhg1 group had slower growth than that in the scramble group. j: Tumor weight in the sh-snhg1 group was lower than that in the scramble group. k: The tumorigenesis and tumor tissue of each group of Balb/C mice (N=6 per group) are shown. Data are presented as the mean value from three independent experiments $\pm$ S.D. * $P < .05$; ** $P < .01$; *** $P < 0.001$; ***** $P < .0001$; NS, no significance.

Figure 3

SNHG1 boosted TERT expression. TCGA data showed that TERT is positively correlated with SNHG1 in pan-cancer (N=9725). (a) and in breast cancer (N=1097) (b). c: Gene Expression Profiling Interactive Analysis (GEPIA) showed that TERT expression level was higher in breast cancer tissues than in normal tissues. d: GEPIA showed that the expression of TERT a higher level in breast cancer tissue than that in normal tissue. e: TERT presents a higher expression level in breast cancer cell lines than in MCF10A cell.

f: TERT showed higher expression level in breast cancer tissues than in paired normal tissues in our own cohort (N=4 per group). g: Transfection efficacy of siSNHG1. h: Knockdown of SNHG1 downregulated TERT mRNA expression in Hs578T and MDA-MB-468 cells. Knockdown of SNHG1 also downregulated TERT protein expression in MDA-MB-468 (i) and Hs578T cells (j). k: TERT protein had a higher expression level in the scramble group than in the sh-snhg1 group. Data are presented as the mean value from three independent experiments $\pm$ S.D. * $P<.05$; ** $P<.01$; *** $P<0.001$; **** $P<.0001$; NS, no significance.

Figure 4

miR-18b-5p acted as a tumor suppressor in breast cancer. a: LncLocator predicted the subcellular localization of SNHG1. b: Subcellular RNA fraction confirmed that SNHG1 was mainly located in the cytoplasm in HEK293T, MDA-MB-468, and Hs578T cells. c: The intersection of TargetScan and StarBase predicted miRNAs. d and e: The upregulated miRNAs after silencing of SNHG1 in MDA-MB-468 and Hs578T cells. f: Expression of TERT after transfecting miR-383-5p mimics in Hs578T cells. g: Transfection efficiency of miR-18b-5p mimics in Hs578T, MDA-MB-468, and MDA-MB-231 cells. h: Colony counting kit-8 proved that miR-18b-5p inhibited cell proliferation. i-k: Colony formation assay, wound healing assay and Transwell invasion assay showed that miR-18b-5p inhibited breast cancer cell colony formation, migration and invasion. Data are presented as the mean value from three independent experiments $\pm$ S.D. * $P < .05$; ** $P < .01$; *** $P < 0.001$; ***** $P < .0001$; NS, no significance.

Figure 5

SNHG1 acted as a ceRNA to enhance TERT expression by sponging miR-18b-5p. a: Transfection efficacy of miR-18b-5p mimics in MDA-MB-468 and Hs578T cells. b and c: Overexpression of miR-18b-5p downregulated TERT mRNA and protein expression. d and e: miR-18b-5p inhibitor upregulated TERT mRNA and protein expression. f and g: Overexpression of miR-18b-5p inhibited SNHG1 expression; however, downregulated miR-18b-5p promoted SNHG1 expression. h: Silencing SNHG1 and inhibiting

miR-18b-5p weakened the downregulation of TERT at the protein level in MDA-MB-468 and Hs578T cells. i and j: A luciferase reporter assay was used to assess the interactions between miR-18b-5p and its binding sites or mutated binding sites in the 3' UTRs of TERT and SNHG1 in HEK293T cells. k and l: siSNHG1-mediated restraint of cell proliferation and invasion abilities was partially rescued by co-transfection of miR-18b-5p inhibitor in Hs578T and MDA-MB-468 cells. m: miR-18b-5p expression in Balb/C mice with snhg1 knockdown (N=5 per group). Data are presented as the mean value from three independent experiments $\pm$ S.D. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$; NS, no significance.

Figure 6

E2F1 promoted SNHG1 transcription. Knockdown efficacy of siE2F1 at mRNA (a) and protein (b) levels in MDA-MB-468, Hs578T, and HEK293T cells. c: Knockdown of E2F1 downregulated SNHG1 expression. d: Knockdown of E2F1 downregulated TERT mRNA expression. e: JASPAR predicted that E2F1 could bind with the promoter of SNHG1. f: Schematic representation of the predicted E2F1 binding sites within the promoter of SNHG1. g and h: Chromatin immunoprecipitation assay showed the binding of E2F1 and SNHG1 promoter region in Hs578T and HEK293T cells. i: Working model of the study. Data are presented as the mean value from three independent experiments $\pm$ S.D. * $P < .05$; ** $P < .01$; *** $P < 0.001$; ***** $P < .0001$; NS, no significance.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.pdf](#)
- [SupplementaryTable1.pdf](#)
- [SupplementaryTable2.pdf](#)
- [SupplementaryTable3.pdf](#)
- [SupplementaryTable4.pdf](#)
- [SupplementaryTable5.pdf](#)
- [Supplementarylegends.pdf](#)